📄 medicine

Rational design of short hybrid Cecropin B/Aurein 1.2 peptide analogues: in vitro synergistic anti-MRSA and anti-biofilm activities

Rationally designed short hybrid peptide Cec-Aur 1 demonstrates potent, low-toxicity anti-MRSA and anti-biofilm activities, including significant synergy with oxacillin and effective wound healing in a murine infection model, positioning it as a promising therapeutic candidate against multidrug-resistant *Staphylococcus aureus*.

Original authors: Maryam Ghahramani, Mohammad Aghazadeh, Javid Sadeghi, Vahdat Poortahmasebi, Amin Abdollahzade-Fard, Mahdieh Delfi, Parisa Hosseini, Reza Akbari

Published 2026-07-14

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Maryam Ghahramani, Mohammad Aghazadeh, Javid Sadeghi, Vahdat Poortahmasebi, Amin Abdollahzade-Fard, Mahdieh Delfi, Parisa Hosseini, Reza Akbari

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the world of bacteria as a bustling, fortified city. For years, the police force (our conventional antibiotics) has been trying to arrest the city's most dangerous criminal: MRSA (Methicillin-Resistant Staphylococcus aureus). But this criminal is tricky. It wears a super-tough armor that makes old police tactics useless, and it builds thick, sticky walls called biofilms that hide it from view and protect it from attacks.

Scientists at Tabriz and Urmia Universities decided to try a new strategy. Instead of using a standard police baton, they decided to design a custom-made "molecular ninja" by mixing two famous warrior peptides: Cecropin B (a soldier from insects) and Aurein 1.2 (a warrior from Australian tree frogs).

The Great Mix-and-Match

The scientists didn't just smash the two warriors together; they used a computer to play "Lego" with their DNA blueprints. They wanted to create a shorter, smarter version that kept the best parts of both: the ability to stick to the enemy's walls and the power to punch holes in them.

They built two prototypes, named Cec-Aur 1 and Cec-Aur 2.

Cec-Aur 1 was the star of the show. It was a 29-amino-acid-long chain with a perfect balance: one side was positively charged (like a magnet for the negatively charged bacterial walls) and the other side was oily and hydrophobic (ready to dive into the membrane).
Cec-Aur 2 was a bit shorter but turned out to be less effective.

The Lab Battle: Shattering the Armor

When they tested Cec-Aur 1 against MRSA in the lab, here is what happened:

The Knockout Punch: The peptide didn't just stop the bacteria from growing; it killed them. At a concentration of 215 µg/mL, it stopped the bacteria from multiplying (the MIC), and at 430 µg/mL, it wiped them out completely (the MBC). It worked fast, too. Within 5 hours, it reduced the number of living bacteria by a massive amount, and by 24 hours, the bacterial population was nearly zero.
The Biofilm Buster: Bacteria love to hide in slime called biofilms. The scientists found that Cec-Aur 1 could dissolve this slime. At a high dose of 512 µg/mL, it stopped 97.62% of the biofilm from forming in a clinical strain. It was like sending a high-pressure hose to wash away the criminal's hiding spot.
The Magic Combo: Here is the coolest part. When the scientists mixed Cec-Aur 1 with an old antibiotic called Oxacillin, something magical happened. The peptide acted like a battering ram, cracking the bacterial door open just enough for the Oxacillin to sneak inside.
- In some strains, this combo made Oxacillin 64 times more effective.
- In others, it made the peptide itself 16 times more effective.
- The "Synergy Score" (FICI) dropped as low as 0.025 in some cases, which is a huge win for teamwork.

The Safety Check: No Friendly Fire

A major problem with many "super-killers" is that they accidentally hurt human cells too. The scientists tested Cec-Aur 1 on human red blood cells and skin cells.

Red Blood Cells: At the doses needed to kill bacteria, the peptide caused 0.02% hemolysis (bursting of cells). This is basically zero. It was as safe as the control group.
Skin and Kidney Cells: When they treated human cells with the peptide, 84% of the kidney cells and 80% of the skin cells survived. This suggests the peptide is very picky, attacking only the bad guys and leaving the good guys alone.

The Real-World Test: The Mouse Wound

To see if this worked in a living body, the scientists created a wound infection on mice using MRSA.

The Result: Mice treated with Cec-Aur 1 saw their bacterial load drop by more than 93%. Their wounds healed faster, looking much cleaner than the untreated mice.
The Twist: When they tried the "Magic Combo" (Peptide + Oxacillin) on the mice, it didn't work as well as the peptide alone. The bacteria weren't reduced as much as they were in the lab.
- Why? The scientists suggest that inside a living body, things are messy. Proteins in the blood, the immune system, and the complex structure of a real wound might have blocked the peptide or changed how the bacteria behaved. While the lab showed perfect teamwork, the living body showed that the peptide alone was the real hero.

What This Means (and What It Doesn't)

The paper concludes that Cec-Aur 1 is a very promising candidate. It is a short, safe, and effective weapon against MRSA that can also break down biofilms and help wounds heal.

However, the authors are careful not to say this is a "cure" yet.

They admit they haven't tested how long the peptide lasts in the blood (stability).
They haven't tested it on every type of bacteria (only Gram-positive so far).
The "Magic Combo" with Oxacillin worked great in the petri dish but didn't show the same super-power in the living mouse, suggesting that real-life biology is more complicated than a lab test.

In short, the scientists have built a tiny, smart, and safe molecular ninja that punches holes in MRSA and helps wounds heal. It's not a finished product ready for the pharmacy shelf, but it's a very strong lead for the future of fighting superbugs.

Technical Summary: Rational Design of Short Hybrid Cecropin B/Aurein 1.2 Peptide Analogues

Problem Statement
The increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and the formation of biofilms have significantly reduced the clinical efficacy of conventional antibiotics, particularly $\beta$ -lactams. While antimicrobial peptides (AMPs) offer a promising alternative due to their broad-spectrum activity and low resistance potential, their clinical translation is hindered by issues such as proteolytic instability, cytotoxicity, and high production costs. There is a critical need for novel, optimized antimicrobial agents that retain potent anti-MRSA and antibiofilm activities while minimizing toxicity to mammalian cells.

Methodology
This study employed a rational design strategy to create short hybrid peptide analogues by fusing functional domains from two parent peptides: Cecropin B (known for its cationic N-terminus and broad-spectrum activity) and Aurein 1.2 (a short, amphipathic peptide from Litoria aurea with potent activity against Gram-positive bacteria).

Design and Modeling: Two analogues, Cec-Aur 1 and Cec-Aur 2, were designed using bioinformatics tools (UCSF Chimera, HeliQuest) to preserve an amphipathic $\alpha$ -helical structure, maintain a positive net charge, and optimize the hydrophobic/hydrophilic balance. Cec-Aur 1 fused the N-terminus of Cecropin B with the C-terminus of Aurein 1.2, while Cec-Aur 2 utilized the middle region of Cecropin B.
Synthesis: The selected peptides were synthesized via microwave-assisted Fmoc solid-phase peptide synthesis and purified to >98% purity.
In Vitro Evaluation:
- Antimicrobial Activity: Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) were determined against five clinical MRSA isolates and reference strains (ATCC 33591, ATCC 29213) using broth microdilution.
- Synergy: Checkerboard assays assessed the interaction between the peptides and Oxacillin, calculating the Fractional Inhibitory Concentration Index (FICI).
- Kinetics: Time-kill kinetics were performed to evaluate bactericidal speed.
- Biofilm: Crystal violet staining measured biofilm inhibition and eradication.
- Safety: Hemolytic activity was tested on human erythrocytes, and cytotoxicity was assessed on HEK-293 and HDF cell lines using MTT assays.
In Vivo Evaluation: A murine excisional wound infection model (BalB/c mice) was used to evaluate the efficacy of Cec-Aur 1 (alone and in combination with Oxacillin) against MRSA, monitoring bacterial burden and wound healing.

Key Contributions and Results

Structural Optimization: The rational design successfully produced shorter peptides with stable amphipathic $\alpha$ -helical structures. Cec-Aur 1 exhibited a favorable balance of net charge (+5.8) and hydrophobicity, distinct from the parent peptides.
Antimicrobial Efficacy: Cec-Aur 1 demonstrated moderate to potent bactericidal activity against all tested MRSA strains, including highly resistant isolates (Oxacillin MIC up to 4096 $\mu$ g/mL). The geometric mean MIC and MBC for Cec-Aur 1 were 215 $\mu$ g/mL and 430 $\mu$ g/mL, respectively. Time-kill assays confirmed rapid, concentration-dependent killing, achieving >3-log reductions in viable counts within 5 hours at 2 $\times$ MIC and 4 $\times$ MIC.
Synergistic Activity: A major finding was the strong synergistic interaction between Cec-Aur 1 and Oxacillin. In 5 out of 6 tested strains, the combination significantly reduced the MIC of Oxacillin. The FICI values ranged from 0.025 to 0.5, indicating synergy. Notably, in the MRSA ATCC 33591 strain, the combination resulted in a 64-fold reduction in the Oxacillin MIC.
Antibiofilm Properties: Cec-Aur 1 inhibited biofilm formation in a dose-dependent manner. In clinical MRSA strains, inhibition reached up to 97.62% at 512 $\mu$ g/mL.
Safety Profile: The peptide exhibited excellent biocompatibility. Hemolysis was negligible (0.02%) at MIC and MBC concentrations. Cytotoxicity assays showed cell viability exceeding 80% in both HEK-293 and HDF cell lines.
In Vivo Performance: In the murine wound model, topical application of Cec-Aur 1 reduced the bacterial burden by more than 93% (1.15-log reduction) compared to untreated controls and promoted accelerated wound healing. However, the combination therapy (Cec-Aur 1 + Oxacillin) did not show a statistically significant synergistic effect in the in vivo wound model compared to the peptide alone, with bacterial counts remaining comparable to the control group in that specific arm.

Significance and Claims
The authors conclude that the rationally designed hybrid peptide Cec-Aur 1 represents a promising candidate for addressing multidrug-resistant S. aureus infections. The study highlights that while Cec-Aur 1 may have a higher MIC than some ultra-potent parent peptides, its therapeutic profile is superior due to:

Enhanced Safety: Negligible hemolysis and low cytotoxicity compared to natural AMPs.
Synergy: The ability to restore susceptibility to Oxacillin in resistant strains in vitro, potentially through membrane permeabilization and modulation of resistance gene expression.
Antibiofilm Activity: Effective inhibition of biofilm formation, a key virulence factor often resistant to conventional antibiotics.
In Vivo Efficacy: Proven ability to reduce bacterial load and promote wound healing in a live animal model.

The paper acknowledges limitations, including the lack of serum stability data, limited cytotoxicity testing to specific cell lines, and the discrepancy between in vitro synergy and in vivo results, attributing the latter to the complexity of biological systems (e.g., serum proteins, tissue penetration, and biofilm heterogeneity). Despite these limitations, the authors assert that Cec-Aur 1 offers a balanced approach, trading some raw potency for improved safety, synergy, and antibiofilm capabilities, making it a viable lead compound for further development.